Journal of Jilin University(Medicine Edition) ›› 2023, Vol. 49 ›› Issue (4): 1099-1106.doi: 10.13481/j.1671-587X.20230435
• Review • Previous Articles
Research progress in pathogenesis and influencing factors of fibrotic pulmonary sarcoidosis
-
Received:2022-06-20Online:2023-07-28Published:2023-07-26
CLC Number:
- R563
Cite this article
share this article
| 1 | BONHAM C A， STREK M E， PATTERSON K C. From granuloma to fibrosis： sarcoidosis associated pulmonary fibrosis［J］.Curr Opin Pulm Med，2016，22（5）： 484-491. |
| 2 | KONIGSBERG I R， MAIER L A， YANG I V. Epigenetics and sarcoidosis［J］. Eur Respir Rev， 2021， 30（160）： 210076. |
| 3 | COLLINS B F， MCCLELLAND R L， HO L A， et al. Sarcoidosis and IPF in the same patient-a coincidence， an association or a phenotype？［J］. Respir Med， 2018， 144S： S20-S27. |
| 4 | CHEN X P， ZHOU Z X， ZHANG Y， et al. NOD2/CARD15 gene polymorphisms and sarcoidosis susceptibility： review and meta-analysis［J］. Sarcoidosis Vasc Diffuse Lung Dis， 2018， 35（2）： 115-122. |
| 5 | LENG D， HUAN C J， XIE T， et al. Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis［J］. PLoS One， 2013， 8（8）： e71059. |
| 6 | BHATTARAI G， LEE Y H， LEE N H， et al. C-myb mediates inflammatory reaction against oxidative stress in human breast cancer cell line， MCF-7［J］. Cell Biochem Funct， 2011， 29（8）： 686-693. |
| 7 | STOCK C J， SATO H， FONSECA C， et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis［J］. Thorax， 2013， 68（5）： 436-441. |
| 8 | LIU Y， LI H， XIAO T， et al. Epigenetics in immune-mediated pulmonary diseases［J］. Clin Rev Allergy Immunol， 2013， 45（3）： 314-330. |
| 9 | MAEDA T， GUAN J Z， HIGUCHI Y， et al. Aging-related alterations of subtelomeric methylation in sarcoidosis patients［J］. J Gerontol A Biol Sci Med Sci， 2009， 64（7）： 752-760. |
| 10 | JENY F， BERNAUDIN J F， VALEYRE D， et al. Hypoxia promotes a mixed inflammatory-fibrotic macrophages phenotype in active sarcoidosis［J］. Front Immunol， 2021， 12： 719009. |
| 11 | BIENER L， KRUSE J， TULETA I， et al. Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis［J］. PLoS One， 2021， 16（2）： e0247197. |
| 12 | LARDOT Y S C. Depressed urokinase activity in bronchoalveolar lavage fluid from patients with sarcoidosis， silicosis or idiopathic pulmonary Rbrosis： relationship to disease severity［J］. Biomarkers，1999，4（5）： 361-372. |
| 13 | KOTANI I， SATO A， HAYAKAWA H， et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis［J］. Thromb Res， 1995， 77（6）： 493-504. |
| 14 | LAZAR M H， CHRISTENSEN P J， DU M， et al. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin［J］. Am J Respir Cell Mol Biol， 2004， 31（6）： 672-678. |
| 15 | ZIEGENHAGEN M W， ROTHE M E， ZISSEL G，et al.Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis［J］. Sarcoidosis Vasc Diffuse Lung Dis， 2002， 19（3）： 185-190. |
| 16 | ZIEGENHAGEN M W， BENNER U K， ZISSEL G， et al. Sarcoidosis： TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers［J］. Am J Respir Crit Care Med， 1997，156（5）： 1586-1592. |
| 17 | ZISSEL G， HOMOLKA J， SCHLAAK J， et al. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis［J］. Am J Respir Crit Care Med， 1996， 154（3 Pt 1）： 713-719. |
| 18 | PIOTROWSKI W J， KISZAŁKIEWICZ J， PASTUSZAK-LEWANDOSKA D， et al. TGF-β and SMADs mRNA expression in pulmonary sarcoidosis［J］. Adv Exp Med Biol， 2015， 852： 59-69. |
| 19 | PIOTROWSKI W J， KISZAŁKIEWICZ J， GÓRSKI P，et al. Immunoexpression of TGF-β/Smad and VEGF-A proteins in serum and BAL fluid of sarcoidosis patients［J］. BMC Immunol， 2015， 16： 58. |
| 20 | KRAAIJVANGER R， JANSSEN BONÁS M， VORSELAARS A D M， et al. Biomarkers in the diagnosis and prognosis of sarcoidosis： current use and future prospects［J］. Front Immunol， 2020， 11： 1443. |
| 21 | BENNETT D， BARGAGLI E， BIANCHI N， et al. Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis［J］. Respir Physiol Neurobiol， 2020， 273： 103323. |
| 22 | D’ALESSANDRO M， VITA E D， BERGANTINI L， et al. Galactin-1， 3 and 9： potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases［J］. Respir Physiol Neurobiol， 2020， 282： 103546. |
| 23 | LIU D H， CUI W， CHEN Q， et al. Can circulating interleukin-18 differentiate between sarcoidosis and idiopathic pulmonary fibrosis？［J］. Scand J Clin Lab Invest， 2011， 71（7）： 593-597. |
| 24 | CINETTO F， AGOSTINI C. Advances in understanding the immunopathology of sarcoidosis and implications on therapy［J］. Expert Rev Clin Immunol， 2016， 12（9）： 973-988. |
| 25 | MOLLER D R， FORMAN J D， LIU M C， et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis［J］. J Immunol， 1996， 156（12）： 4952-4960. |
| 26 | EISENSTEIN E M， WILLIAMS C B. The Treg/Th17 cell balance： a new paradigm for autoimmunity［J］. Pediatr Res， 2009， 65（7）： 26-31. |
| 27 | KOLAHIAN S， FERNANDEZ I E， EICKELBERG O， et al. Immune mechanisms in pulmonary fibrosis［J］. Am J Respir Cell Mol Biol， 2016， 55（3）： 309-322. |
| 28 | CELADA L J， KROPSKI J A， HERAZO-MAYA J D， et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production［J］. Sci Transl Med， 2018， 10（460）： eaar8356. |
| 29 | DANIIL Z， KITSANTA P， KAPOTSIS G， et al. CD8+T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosis［J］.Respir Res，2005，6（1）： 81. |
| 30 | SHENDEROV K， COLLINS S L， POWELL J D，et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis［J］. J Clin Invest， 2021， 131（2）： e143226. |
| 31 | GODA C， BALLI D， BLACK M， et al. Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway［J］. PLoS Genet， 2020， 16（4）： e1008692. |
| 32 | LIU G X， ZHAI H Q， ZHANG T， et al. New therapeutic strategies for IPF：based on the “phagocytosis- secretion-immunization” network regulation mechanism of pulmonary macrophages［J］.Biomedecine Pharmacother， 2019， 118： 109230. |
| 33 | SUN L， LOUIE M C， VANNELLA K M， et al. New concepts of IL-10-induced lung fibrosis： fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis［J］. Am J Physiol Lung Cell Mol Physiol， 2011， 300（3）： L341-L353. |
| 34 | PECHKOVSKY D V， PRASSE A， KOLLERT F，et al.Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction［J］. Clin Immunol， 2010， 137（1）： 89-101. |
| 35 | CHENG P， LI S， CHEN H. Macrophages in lung injury， repair， and fibrosis［J］. Cells， 2021， 10（2）： 436. |
| 36 | KAMPHUIS L S， VAN ZELM M C， LAM K H，et al. Perigranuloma localization and abnormal maturation of B cells： emerging key players in sarcoidosis？［J］. Am J Respir Crit Care Med， 2013， 187（4）： 406-416. |
| 37 | BERGANTINI L， CAMELI P， D'ALESSANDRO M， et al. NK and NKT-like cells in granulomatous and fibrotic lung diseases［J］. Clin Exp Med， 2019， 19（4）： 487-494. |
| 38 | SAKULA A. Bronchial carcinoma and sarcoidosis［J］. Br J Cancer， 1963， 17（2）： 206-212. |
| 39 | VERLEDEN G M， DU BOIS R M， BOUROS D，et al. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin［J］. Eur Respir J Suppl， 2001， 32： 17s-29s. |
| 40 | RADISKY D C， KENNY P A， BISSELL M J. Fibrosis and cancer： do myofibroblasts come also from epithelial cells via EMT？［J］. J Cell Biochem， 2007， 101（4）： 830-839. |
| 41 | JAMMAL T E， PAVIC M， GERFAUD-VALENTIN M，et al. Sarcoidosis and cancer： a complex relationship［J］. Front Med （Lausanne）， 2020， 7： 594118. |
| 42 | MIMURA K， MOCHIZUKI Y， NAKAHARA Y，et al. A case of primary lung cancer with swollen mediastinal lymph nodes due to pre-existing sarcoidosis［J］. J Jpn Respir Soc， 2011， 49（3）： 208-213. |
| 43 | MURAMATSU M， KURIYAMA M， TAKAHASHI K，et al. A case of resected squamous cell carcinoma of the lung complicated with sarcoidosis［J］. J Jpn Respir Soc， 2000， 38（9）： 720-725. |
| 44 | JEUNE I L， GRIBBIN J， WEST J， et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK［J］. Respir Med， 2007， 101（12）： 2534-2540. |
| 45 | YATIM N， MATEUS C， CHARLES P. Sarcoidosis post-anti-PD-1 therapy， mimicking relapse of metastatic melanoma in a patient undergoing complete remission［J］. Rev Med Interne， 2018， 39（2）： 130-133. |
| 46 | JAMES W E， JUDSON M A. Therapeutic strategies for pulmonary sarcoidosis［J］. Expert Rev Respir Med， 2020， 14（4）： 391-403. |
| 47 | Statement on sarcoidosis. Joint statement of the American thoracic society （ATS）， the European respiratory society （ERS） and the world association of sarcoidosis and other granulomatous disorders （WASOG） adopted by the ATS board of directors and by the ERS executive committee， February 1999［J］. Am J Respir Crit Care Med， 1999， 160（2）： 736-755. |
| 48 | BELPERIO J A， SHAIKH F， ABTIN F G， et al. Diagnosis and treatment of pulmonary sarcoidosis［J］. JAMA， 2022， 327（9）： 856. |
| 49 | GERKE A K. Treatment of sarcoidosis： a multidisciplinary approach［J］. Front Immunol， 2020， 11： 545413. |
| 50 | LE V， CROUSER E D. Potential immunotherapies for sarcoidosis［J］. Expert Opin Biol Ther， 2018， 18（4）： 399-407. |
| 51 | WOLLIN L， MAILLET I， QUESNIAUX V， et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis［J］. J Pharmacol Exp Ther， 2014， 349（2）： 209-220. |
| 52 | GHAZIPURA M， MAMMEN M J， HERMAN D D， et al. Nintedanib in progressive pulmonary fibrosis： a systematic review and meta-analysis［J］. Ann Am Thorac Soc， 2022， 19（6）： 1040-1049. |
| 53 | WUYTS W A， PAPIRIS S， MANALI E， et al. The burden of progressive fibrosing interstitial lung disease： a DELPHI approach［J］. Adv Ther， 2020， 37（7）： 3246-3264. |
| 54 | RICHELDI L， KOLB M， JOUNEAU S， et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis［J］. BMC Pulm Med， 2020， 20（1）： 3. |
| 55 | WELLS A U， FLAHERTY K R， BROWN K K， et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial： a randomised， double-blind， placebo-controlled， parallel-group trial［J］. Lancet Respir Med，2020，8（5）： 453-460. |
| 56 | CONTE E， GILI E， FAGONE E， et al. Effect of pirfenidone on proliferation，TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts［J］. Eur J Pharm Sci， 2014， 58： 13-19. |
| 57 | KORSTEN P， STROHMAYER K， BAUGHMAN R P，et al. Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach［J］. Clin Pulm Med， 2016， 23（2）： 67-75. |
| 58 | BRAUN N A， CELADA L J， HERAZO-MAYA J D， et al. Blockade of the programmed death-1 pathway restores sarcoidosis CD4（+） T-cell proliferative capacity［J］.Am J Respir Crit Care Med，2014，190（5）： 560-571. |
| 59 | CELADA L J， ROTSINGER J E， YOUNG A， et al. Programmed death-1 inhibition of phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling impairs sarcoidosis CD4+ T cell proliferation［J］. Am J Respir Cell Mol Biol， 2017， 56（1）： 74-82. |
| 60 | PAOLETTI L， WHELAN T P M. Lung transplantation for interstitial lung disease［J］. Curr Respir Care Rep， 2014， 3（3）： 96-102. |
| [1] | Xiao LIN,Meng ZHOU,Fan LIN,Xiujuan YAO. Bioinformatics analysis and experimental validation of fatty acid metabolism-related genes in idiopathic pulmonary fibrosis tissue [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 93-104. |
| [2] | Xianwei JIANG,Minghang WANG,Huiru LI,Xiaosheng DONG,Yuanyuan LIU. Mendelian randomization and GEO database identification analysis based on potential therapeutic targets for chronic obstructive pulmonary disease [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 1072-1083. |
| [3] | Liang LI,Xiangdong ZHOU,Jie WANG,Chaoqun XU,Mengxia ZHU,Shanjun YU,Qi LI. Effect of bitter-taste receptor T2R38 activation on ferroptosis of human airway epithelium NuLi-1 cells induced by cigarette smoke exposure and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 333-340. |
| [4] | Peiqin JIANG,Zheng ZHANG,Zhong HUANG,Xianling LU. Expressions of autotaxin and lysophosphatidic acid receptor 3 in serum and lung tissue of patients with chronic obstructive pulmonary disease and their significances [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 191-201. |
| [5] | Yang XUE,Yingxin RUAN,Tiekun YAN,Junya JIA,Shan LIN. Ameliorative effect of ACE2/Ang（1-7）/Mas axis on high-turover bone disease in uremic rats [J]. Journal of Jilin University(Medicine Edition), 2025, 51(1): 26-33. |
| [6] | Guangwen LONG,Qian ZHANG,Xiulin YANG,Hongpeng SUN,Chunling JI. Improvement effect of inhibiting miR-193a-5p expression on pulmonary fibrosis in rats with acute respiratory distress syndrome and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1491-1498. |
| [7] | Jialiang CHEN,Qi LI,Xiangdong ZHOU,Xiaomei CHEN,Feng LIU,Chang LIU,Youqing ZHONG,Liang LI. Inhibitory effect of nobiletin on airway mucus hypersecretion in model rats with chronic obstructive pulmonary disease and its molecular mechanism [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 295-302. |
| [8] | Yu ZHANG,Xianling LU. Expressions of IL-33, IL-8, and NETs in lung tissue of patients with chronic obstructive pulmonary disease and their significances [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 498-507. |
| [9] | . Research progress in application of metagenomic next-generation sequencing technology in pathogenic detection of lung infection [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1382-1387. |
| [10] | Haixin QU,Erwei YUAN,Weiping GUO,Yajing ZHANG,Wenxia MA,Dan WU. Improvement effect of luteolin on acute respiratory distress syndrome by inhibiting ROS/TXNIP/NLRP3 signaling pathway activation in mice [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 676-683. |
| [11] | Ming LI,Qiuting WANG,Shan CHEN,Huifang SHI. Improvement effect of p38 MAPK inhibitor on chronic obstructive pulmonary disease injury in mice through inhibiting cell pyrotosis mediated by NLRP3 pathway [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 744-754. |
| [12] | Luowei HE,Ye WANG,Dujuan YU,Zhiying CHEN. Chlamydia psittaci pneumonia:A report of 2 cases and literature review [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 222-227. |
| [13] | Qian LI,Jiaqi ZHOU,Jingyi YUAN,Min ZHAO,Xin DI,Ke WANG. Spindle cell carcinoma of lung: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1557-1561. |
| [14] | Cong WANG, Xiu GUO, Hao CHI, Jie ZHANG, Mingyu XU, Chunling DONG. Application values of simplified Wells score, revised Geneva score and D-dimer level in diagnosis of malignant tumor complicated with pulmonary thromboembolism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 707-713. |
| [15] | . [J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 237-242. |